H.C. Wainwright raised the firm’s price target on Belite Bio (BLTE) to $185 from $98 and keeps a Buy rating on the shares after the company reported positive topline results from the Phase 3 DRAGON trial of tinlarebant in adolescent Stargardt disease. In the wake of the DRAGON trial update, the firm has increased its view of the probability of approval for tinlarebant in STGD1 to 85% from 65%, the analyst noted.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE: